Pediatrix Medical Group (NYSE:MD) Price Target Raised to $15.00 at Mizuho

Pediatrix Medical Group (NYSE:MD) had its price objective boosted by Mizuho from $13.00 to $15.00 in a report issued on Tuesday,Benzinga reports. Mizuho currently has a neutral rating on the stock.

Several other research analysts have also weighed in on MD. StockNews.com upgraded Pediatrix Medical Group from a “hold” rating to a “buy” rating in a report on Wednesday, November 13th. Jefferies Financial Group lifted their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Truist Financial lifted their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Deutsche Bank Aktiengesellschaft lifted their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Finally, UBS Group lifted their target price on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $16.10.

Pediatrix Medical Group Stock Up 1.4 %

NYSE:MD opened at $14.96 on Tuesday. Pediatrix Medical Group has a 12-month low of $6.62 and a 12-month high of $16.41. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. The firm has a market capitalization of $1.28 billion, a P/E ratio of -4.89, a P/E/G ratio of 2.08 and a beta of 1.55. The stock’s fifty day simple moving average is $12.84 and its 200-day simple moving average is $10.00.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The business had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. During the same period last year, the company earned $0.29 EPS. The firm’s revenue was up .9% on a year-over-year basis. Equities research analysts expect that Pediatrix Medical Group will post 1.26 earnings per share for the current year.

Insider Buying and Selling at Pediatrix Medical Group

In related news, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the sale, the chief executive officer now owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. The trade was a 6.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Mary Ann E. Moore sold 8,108 shares of Pediatrix Medical Group stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the transaction, the executive vice president now owns 135,810 shares of the company’s stock, valued at $2,172,960. The trade was a 5.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 53,808 shares of company stock valued at $751,277 in the last 90 days. 2.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of hedge funds and other institutional investors have recently bought and sold shares of MD. nVerses Capital LLC bought a new position in Pediatrix Medical Group during the second quarter worth about $31,000. Innealta Capital LLC bought a new position in Pediatrix Medical Group during the second quarter worth about $33,000. Quest Partners LLC grew its holdings in Pediatrix Medical Group by 25.6% during the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock worth $35,000 after purchasing an additional 622 shares during the period. Nisa Investment Advisors LLC grew its holdings in Pediatrix Medical Group by 47.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after purchasing an additional 1,524 shares during the period. Finally, Quarry LP grew its holdings in Pediatrix Medical Group by 54.1% during the third quarter. Quarry LP now owns 4,735 shares of the company’s stock worth $55,000 after purchasing an additional 1,662 shares during the period. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.